Effects of amifostine (WR-2721, ethyol) on tumor growth and pharmacology of cytotoxic drugs in human xenotransplanted neuroblastomas

Anti-Cancer Drugs

Volumn 8, Issue 2, 1997, Pages 174-181

  Fichtner, I ^a   Lemm, M ^a   Becker, M ^a   Berthold, F ^b  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Amifostine; Chemoprotection; Cytostatics; Neuroblastoma; Side effects; Tumor growth; Xenografts

Indexed keywords

AMIFOSTINE; CHEMOPROTECTIVE AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; RADIOPROTECTIVE AGENT; UNCLASSIFIED DRUG; VINCRISTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GRAFT; CONTROLLED STUDY; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; LEUKOPENIA; MOUSE; NEUROBLASTOMA; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TUMOR GROWTH; WEIGHT REDUCTION; XENOGRAFT;

EID: 0031055257     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199702000-00008     Document Type: Article

References (21)

1. Peter GJ, van der Vijgh WJ. Protection of normal tissues from the cytotoxic effects of chemotherapy and radiation by amifostine (WR-2721): preclinical aspects. Eur J Cencer 1995; 31A (suppl 1): 1-7.
2. van der Vijgh WJI, Peters GJ. Protection of normal tissues from the cytotoxic effects of chemotherapy and radiation by amifostine (ethyol): preclinical aspects. Semin Oncol 1994; 21 (suppl 11): 2-7.
3. Calabro-Jones PM, Fahey RC, Smoluk GD. Ward JE Alkaline phosphatase promotes radioprotection and accumulation of WR-1065 in V9-171 cells incubated in medium containing WR 2721. Int J Radiat Biol 1985; 47: 23-7.
4. Tahsildar HI, Biaglow JE, Ligerman MM, et al. Factors influencing the oxidation of the radioprotector WR-1065. Radial Res 1988; 113: 243-51.
5. Yang J-L, Fernandes DJ, Speicher L, et al. Biochemical determinants of the cytoprotective effect of amifostine. Proc Am Ass Cancer Res 1995; 36: 290.
6. Murley JS, Grdina DJ. The effects of cycloheximide and WR-1065 on radiation-induced repair processes: a mechanism for chemoprevention. Carcinogenesis 1995; 16: 2699-705.
7. Kyoizumi S, McCune JM, Namikawa R. Direct evaluation of radiation damage in human hematopoietic progenitor cells in vivo. Radiat Res 1994; 137: 76-83.
8. Patchen ML, MacVittie TJ. Granulocyte colony-stimulating factor and amifostine (ethyol) synergize to enhance hemopoietic reconstitution and increase survival in irradiated animals. Semin Oncol 1994; 21 (5 suppl 11): 26-32.
9. Durand RE, Olive PL. Radiosenssitisation and radioprotection by BSO and WR-2721: the role of oxygenation. Br J Cancer 1989; 60: 517-522.
10. Shaw L. Bonner H, Nakashima H, Lieberman R. Pharmacokinetics of amifostine in cancer patients: evidence for saturable metabolism. Proc Am Soc Clin Oncol 1994; 13: 144.
11. Spencer CM, Goa KL. Amifostine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as a radioprotector and cytotoxic chemoprotector. Drugs 1995; 50: 1001-31.
12. Borsi JD, Csaki C, Ferencz T, Oster W. Administration of ethyol (amifostine) to a child with medulloblastoma to ameliorate hematological toxicity of high dose carbopolatin. Anti-Cancer Drugs 1996; 7: 121-6.
13. Treskes M, Woven E, van de Loosdrecht AA. et al. Effects of the modulating agent WR 2721 on myelotoxicities and antitumour activity in carboplatin treated mice. Eur J Cancer 1994; 30A: 183-7.
14. Yuhas JM, Spellman JM, Jordan SW, et al. Treatment of tumours with the combination of WR-2721 and cis dichlorodiammineplatinum (II) or cyclophosphamide. Br J Cancer 1980; 42: 574-85.
15. Jones MM, Basinger MA, Holscher MA. Relative effectiveness of some compounds for the control of cisplatin-induced nephrotoxicity. Toxicology 1991; 68 227-47.
16. Twentyman PR. Modification by WR-2721 of the response to chemotherapy of tumours and normal tissues in the mouse. Br J Cancer 1983; 47: 57-63.
17. Capizzi RL, Oster W. Protection of normal tissue from the cytotoxic effects of chemotherapy and radiation by amifostine: clinical experiences. Eur J Cancer 1995; 31A (suppl 1): 8-13.
18. Fulda S, Oster W, Berthold F. Effects of WR-2721 (amifostine) and its metabolite WR-1065 on the antiproliferative activity of chemotherapeutic agents on neuroblastoma cells in vitro. Anti-cancer Drugs, 8: 34-41.
19. Fulda S. Die antiproliferative Wirkung von Alkylanzien, Platinderivaten, Antimetaboliten und Zilascorh auf sechs humane neuroektodermale Zellinien in vitro. Inaugural-Dissertation, Universität Köln, 1995.
20. Ambros PF, Ambros IM, Ladenstein R, Gadner H. Neuroblastoma: impact of biological characteristics on treatment strategies. Onkologie 1995; 18: 548-555.
21. Fulda S, Honer M, Menke-Moellers I, Berthold F. Antiproliferative potential of cytostatic drugs on neuroblastoma cells in vitro. Eur J Cancer 1995; 31A: 616-21.